This company is no longer active
Diffusion Pharmaceuticals Management
Management criteria checks 3/4
Diffusion Pharmaceuticals' CEO is Bob Cobuzzi, appointed in Sep 2020, they has a tenure of 2.92 years. Their total yearly compensation is $691.79K , comprised of 65% salary and 35% bonuses, including company stock and options. They directly owns 0.079% of the company’s shares, worth $10.66K. The average tenure of the management team and the board of directors is 4.9 years and 1.8 years respectively.
Key information
Bob Cobuzzi
Chief executive officer
US$691.8k
Total compensation
| CEO salary percentage | 65.0% |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.08% |
| Management average tenure | 4.9yrs |
| Board average tenure | 1.8yrs |
Recent management updates
Recent updates
Diffusion Pharmaceuticals GAAP EPS of -$2.06 misses by $0.02
Aug 12We Think Diffusion Pharmaceuticals (NASDAQ:DFFN) Needs To Drive Business Growth Carefully
Feb 25
Companies Like Diffusion Pharmaceuticals (NASDAQ:DFFN) Are In A Position To Invest In Growth
Nov 12We're Not Very Worried About Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Rate
Jun 25Diffusion Pharmaceuticals EPS misses by $0.02
May 10We're Hopeful That Diffusion Pharmaceuticals (NASDAQ:DFFN) Will Use Its Cash Wisely
Mar 08Here's Why We're Watching Diffusion Pharmaceuticals' (NASDAQ:DFFN) Cash Burn Situation
Nov 23CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2023 | n/a | n/a | -US$13m |
| Mar 31 2023 | n/a | n/a | -US$15m |
| Dec 31 2022 | US$692k | US$450k | -US$16m |
| Sep 30 2022 | n/a | n/a | -US$15m |
| Jun 30 2022 | n/a | n/a | -US$24m |
| Mar 31 2022 | n/a | n/a | -US$24m |
| Dec 31 2021 | US$783k | US$410k | -US$24m |
| Sep 30 2021 | n/a | n/a | -US$25m |
| Jun 30 2021 | n/a | n/a | -US$17m |
| Mar 31 2021 | n/a | n/a | -US$18m |
| Dec 31 2020 | US$1m | US$129k | -US$16m |
Compensation vs Market: Bob's total compensation ($USD691.79K) is about average for companies of similar size in the US market ($USD762.43K).
Compensation vs Earnings: Bob's compensation has been consistent with company performance over the past year.
CEO
Bob Cobuzzi (58 yo)
2.9yrs
Tenure
US$691,787
Compensation
Dr. Robert J. Cobuzzi, Jr., also known as Bob, Ph D., serves as its President & Chief Executive Officer at Diffusion Pharmaceuticals Inc. since September 8, 2020 served as its Independent Director since Ja...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & CEO | 2.9yrs | US$691.79k | 0.079% $ 10.7k | |
| General Counsel & Corporate Secretary | 2.9yrs | US$413.92k | 0.020% $ 2.6k | |
| Senior Medical Advisor | 10.9yrs | no data | no data | |
| Vice President of Clinical Operations | 6.9yrs | no data | no data | |
| Senior Consultant for Manufacturing | no data | no data | no data | |
| Senior Consultant - Regulatory Affairs | no data | no data | no data |
4.9yrs
Average Tenure
58yo
Average Age
Experienced Management: DFFN's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 7.6yrs | US$59.00k | 0.0016% $ 218.1 | |
| Independent Chairman | 2.9yrs | US$77.50k | 0.060% $ 8.1k | |
| Lead Independent Director | 7.6yrs | US$55.50k | 0.053% $ 7.1k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 7.6yrs | US$54.00k | 0.0035% $ 468.6 | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Independent Director | 2.2yrs | US$49.00k | 0.014% $ 1.9k | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 1.5yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
1.8yrs
Average Tenure
61yo
Average Age
Experienced Board: DFFN's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/08/17 02:30 |
| End of Day Share Price | 2023/08/17 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Diffusion Pharmaceuticals Inc. is covered by 3 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| David Bautz | Zacks Investment Research Inc. |
| David Bautz | Zacks Small-Cap Research |